Seres Therapeutics’ proprietary discovery and design platform enables us to identify key alterations in the microbiome that are associated with or lead to specific diseases, and to rationally design tailored therapies that disrupt the disease state and establish a healthy microbiome.
Our lead Phase 3 development candidate, SER-109, is an investigational oral microbiome therapeutic for the prevention of Clostridium difficile infection (CDI) in adults with multiply recurrent CDI. The FDA has designated SER-109 as both a Breakthrough Therapy and an Orphan Drug.
We are currently evaluating SER-262, the first synthetically-derived and designed microbiome therapeutic ever to reach clinical-stage development, in a Phase 1b study in patients with primary Clostridium difficile infection.
We are developing Ecobiotic® drugs to treat inflammatory bowel disease, including Ulcerative Colitis (UC) and reported positive results of our Phase 1b study of SER-287 in patients with ulcerative colitis.
In addition, we are developing SER-401, a preclinical stage oral microbiome therapy comprising a rationally-designed consortium of live bacteria, to improve the efficacy and safety of immunotherapy. Through a collaboration with The University of Texas MD Anderson Cancer Center and the Parker Institute for Cancer Immunotherapy, we are initiating a randomized, placebo-controlled clinical study in patients with advanced metastatic melanoma. Read more about this collaboration here.
We are also researching the use of Ecobiotic® drugs for the treatment of additional inflammatory diseases and metabolic diseases.